Amgen’s Q3 Sales Beat Consensus, But Two Key New Drugs Fell Short

 
• By Mandy Jackson

Revenue from migraine prophylaxis Aimovig shrank from Q2 levels, while cholesterol-lowering Repatha volume increased, but sales came in below consensus.

Business report
Aimovig and Repatha were below consensus, but Enbrel, Evenity and biosimilars beat expectations. • Source: Shutterstock

More from Earnings

More from Business